Betsy LaPlant

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

Wei Ding, Betsy LaPlant, Timothy G. Call et al. · Blood · 2017 · 412 citations · Full text

Medicine, Clinical Sciences, Oncology +6

Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non–Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study

Grzegorz S. Nowakowski, Betsy LaPlant, William R. Macon et al. · Journal of Clinical Oncology · 2014 · 364 citations · Full text

Medicine, Hematology, Oncology +16

Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma

Stephen M. Ansell, Sara A. Hurvitz, Patricia Koenig et al. · Clinical Cancer Research · 2009 · 332 citations · Full text

Medicine, Oncology, Pharmacology +17

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

Karla V. Ballman, Jan C. Buckner, Paul D. Brown et al. · Neuro-Oncology · 2006 · 318 citations · Full text

Medicine, Oncology, Neuro-oncology +16

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

Thomas E. Witzig, Craig B. Reeder, Betsy LaPlant et al. · Leukemia · 2010 · 299 citations · Full text

Medicine, Oncology, Pharmacology +15